Skip to main content
. 2018 Jan 11;13(1):e0190302. doi: 10.1371/journal.pone.0190302

Table 3. Relative hazard of time to FIB4 progression.

  Relative hazards of time to Fib4 progression
  Unadjusted RH(95% CI) p-value Adjusted RH(95% CI) p-value
Tropism
    R5 1.00 1.00
    X4 0.99 (0.70, 1.40) 0.952 0.86 (0.59, 1.26) 0.444
Mode of HIV Transmission
    PWID 1.00 1.00
    MSM 0.61 (0.35, 1.05) 0.076 1.05 (0.62, 1.76) 0.776
    Heterosexual contacts 0.69 (0.40, 1.19) 0.188 0.86 (0.52, 1.42) 0.868
Calendar year of test
    per more recent 1.13 (1.06, 1.20) < .001 0.76 (0.44, 1.32) 0.324
Age, years
    per 10 years older 1.44 (1.25, 1.65) < .001 1.40 (1.20, 1.64) < .001
CD4 count, cells/mmc
    <200 1.00 1.00
    201–350 0.53 (0.27, 1.06) 0.074 0.68 (0.29, 1.61) 0.383
    >350 0.52 (0.31, 0.89) 0.018 1.07 (0.51, 2.24) 0.850
    Unknown 0.65 (0.39, 1.10) 0.106 0.85 (0.23, 3.07) 0.799
CD4 count nadir, cells/mmc
    <200 1.00 1.00
    201–350 0.67 (0.44, 1.03) 0.071 1.04 (0.61, 1.76) 0.887
    >350 0.64 (0.45, 0.92) 0.015 1.00 (0.60, 1.67) 0.986
    Unknown 1.15 (0.49, 2.70) 0.756 1.08 (0.39, 2.77) 0.867
Viral load, log10 copies/mL
    <5000 1.00 1.00
    5000–10000 0.85 (0.33, 2.19) 0.741 1.21 (0.44, 3.34) 0.708
    10000–100000 0.99 (0.58, 1.69) 0.972 1.42 (0.79, 2.61) 0.257
    >100000 1.46 (0.86, 2.48) 0.158 2.05 (1.13, 3.81) 0.022
    Unknown 1.22 (0.79, 1.90) 0.374 1.89 (0.53, 6.80) 0.332
Aids diagnosis
    Yes vs. No 1.70 (1.08, 2.67) 0.021 1.65 (0.97, 2.80) 0.066
ART exposure status
    Not Naïve 1.00 1.00
    Naïve 0.69 (0.50, 0.94) 0.018 0.63 (0.43, 0.94) 0.024
Time from HIV diagnosis to date of tropism test
    per more recent 1.01 (1.01, 1.02) < .001 1.04 (0.99, 1.09) 0.114
HCV infection
    No 1.00 1.00
    Yes 2.23 (1.43, 3.49) < .001 3.30 (1.92, 5.67) < .001
    Not tested 0.87 (0.33, 2.29) 0.779 0.65 (0.24, 1.73) 0.387
Diabetes
    Yes vs. No 3.47 (1.54, 7.78) 0.003 3.63 (1.54, 8.62) 0.003

Adjusted for a number of factors measured at the time of tropism test—mode of HIV transmission, nationality, AIDS diagnosis, B/C co-infection status, calendar year, age, CD4 count, CD4 nadir, HIV-RNA, diabetes, use of lipids/blood pressure lowering drugs, ART exposure status and stratified by clinical site.